Ave Science & Technology (688067.SH) has won the second prize of Hubei Province Science and Technology Progress Award.
Aiwu Technology (688067.SH) announced that the company has recently received the Science and Technology Award Certificate issued by the Hubei Provincial People's Government. The project "Key Technological Innovation and Clinical Application of Acute Leukemia Bone Marrow Molecular Diagnosis" participated and completed by the company was awarded the second prize of the Hubei Province Science and Technology Progress Award for the year 2025.
Ave Science & Technology (688067.SH) announced that the company recently received a science and technology award certificate issued by the Hubei Provincial People's Government. The project "Key Technological Innovation and Clinical Application of Acute Leukemia Bone Marrow Molecular Diagnosis" participated in by the company was awarded the second prize of the 2025 Hubei Provincial Science and Technology Progress Award.
This award is a full recognition of the company's technological innovation and research and development capabilities. In the future, the company will continue to increase its efforts in scientific research, continuously improve its technological innovation capabilities, and further enhance its core competitiveness.
Related Articles
Teamway International Group Limited (01239) issued 39.45 million shares for subscription, raising approximately 134 million Hong Kong dollars.
Shenzhen Kangtai Biological Products (300601.SZ): Application for clinical trial of adsorbed acellular pertussis (components) combined vaccine (for adults, teenagers, and children) has been accepted.
On January 8, LIANLIAN (02598) spent HK$954,000 to repurchase 140,000 shares.
Teamway International Group Limited (01239) issued 39.45 million shares for subscription, raising approximately 134 million Hong Kong dollars.
Shenzhen Kangtai Biological Products (300601.SZ): Application for clinical trial of adsorbed acellular pertussis (components) combined vaccine (for adults, teenagers, and children) has been accepted.
On January 8, LIANLIAN (02598) spent HK$954,000 to repurchase 140,000 shares.
RECOMMEND
Bank Of America Sees Three Drivers Supporting Chinese Consumer Stocks: Low Base, Deep Undervaluation, And Convertible‑Like Defensive Traits
07/01/2026
Cross‑Border E‑Commerce In 2025: Tariffs, Trade Wars, And Shifting Away From The United States
07/01/2026
Asian Stock Markets Record The Strongest Annual Start Ever As Shanghai Composite Hits Multi‑Year High And Sets Longest Winning Streak; Japan And Korea Rally
07/01/2026
